Payment overview · 2025
General Payments
$529.73
16 reported records · 8 companies
Healthcare provider profile · identity verified
Michael L. Smith, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · GILBERT, AZ · NPI 1760782973
Verified facts
What the public records show
CMS Open Payments records show Michael L. Smith, M.D received $529.73 in general payments during 2025 across 16 reported records.
Edwards Lifesciences Corporation accounted for 35.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $187.03 | 35.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $82.52 | 15.6% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $68.63 | 13.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.97 | 11.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.31 | 10.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.16 | 7.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.67 | 3.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.44 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $529.73 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $187.03 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $82.52 | 4 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $68.63 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.97 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.31 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.04 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 304 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 239 | 78 |
| Losartan Potassium | Losartan Potassium | 218 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 201 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 190 | 70 |
| Metformin Hcl | Metformin Hcl | 141 | 51 |
| Lisinopril | Lisinopril | 125 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 53 |
| Alendronate Sodium | Alendronate Sodium | 95 | 36 |
| Gabapentin | Gabapentin | 95 | 35 |
| Jardiance | Empagliflozin | 78 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 25 |
| Omeprazole | Omeprazole | 70 | 22 |
| Alprazolam | Alprazolam | 69 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 25 |
| Trazodone Hcl | Trazodone Hcl | 54 | 16 |
| Prednisone | Prednisone | 52 | 35 |
| Atenolol | Atenolol | 51 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 19 |
| Simvastatin | Simvastatin | 50 | 18 |
| Eliquis | Apixaban | 48 | 15 |
| Ezetimibe | Ezetimibe | 47 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 47 | 20 |
| Tramadol Hcl | Tramadol Hcl | 41 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 13 |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Allopurinol | Allopurinol | 39 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 16 |
| Furosemide | Furosemide | 37 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 15 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | 14 |
| Potassium Chloride | Potassium Chloride | 34 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Famotidine | Famotidine | 33 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 13 |
| Montelukast Sodium | Montelukast Sodium | 33 | 15 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Glipizide Er | Glipizide | 30 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 26 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $529.73 · 16 records | Edwards Lifesciences Corporation | Cologuard Collection Kit, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, OTEZLA, REPATHA, SAPIEN 3 Ultra RESILIA, TZIELD, The Cologuard Plus Collection Kit, Veozah, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error